Amikacin is a semisynthetic derivative of kanamycin and primarily active against aerobic Gram-negative-pathogens with limited activity against Gram-positive bacteria. Meager study was reported on pharmacokinetic data on multi-days administration of amikacin. Hence, pharmacokinetics study was done in five clinically healthy goats (n = 5), after intravenous bolus injection of amikacin sulfate at the dose rate of 10 mg/kg body weight daily for three consecutive days. The amikacin concentrations in plasma and pharmacokinetics-parameters were analyzed by using microbiological assay technique and non-compartmental open-model, respectively. The mean peak plasma concentrations (Mean ± SD) of amikacin at time zero (Cp∨0) was 114.19 ± 20.78 and 128.67 ± 14.37 ㎍/mL, on day 1st and 3rd, respectively. The mean elimination half-life (t∧1/2ke) was 1.00 ± 0.28 h on day 1st and 1.22 ± 0.29 h on day 3rd. Mean of area under concentration-time curve (AUC∧0→∞) was 158.26 ± 60.10 and 159.70 ± 22.74 ㎍.h/mL, on day 1st and 3rd respectively. The total body clearance (Cl∧B) and volume of distribution at steady state (Vdss) on day 1st and 3rd were Cl∧B = 0.07 ± 0.02 and 0.06 ± 0.01 L/h.kg and Vdss = 0.10 ± 0.03 and 0.11 ± 0.05 L/kg, respectively. No-significant difference was noted in both drug-plasma concentration and pharmacokinetics-parameters, respectively. Amikacin concentration in plasma was found higher up-to 4 h and 6 h onward on down-ward trends favour to reduce toxicity. Which also support the pharmacokinetic-pharmacodynamic way of dosing of aminoglycosides and hence, amikacin may be administered 10 mg/kg intravenously daily to treat principally Gram-negative pathogens and limitedly Gram-positive-pathogens.